trial

Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia

NCTId NCT02411695
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 43 (actual)
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.
Primary completion 2017-01-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
43 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Parallel
Masking
None
Start
2015-03
Primary completion
2017-01-01
Eligibility
ALL · 13 Years · 17 Years

Interventions & indications

Drugs
Brexpiprazole (Rexulti)

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.Lead Sponsor
H. Lundbeck A/SCollaborator

Sites

0 total

Facts & assertions

4 sourced
Enrollment
43
Phase
PHASE1
Primary Completion Date
2017-01-01
Status
COMPLETED
relationships
The graph out of here
drug
Brexpiprazole (Rexulti)
drug
lead_sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
company
collaborator
H. Lundbeck A/S
company
indication
Schizophrenia
indication
Schizophrenia
indication